Drawing based on the label description. No photo yet.
“Buprenorphine and naloxone sublingual tablets containing 2 mg buprenorphine with 0.5 mg naloxone (in terms of free base, equivalent to 2.16 mg buprenorphine hydrochloride USP and 0.61 mg naloxone hydrochloride dihydrate USP) are uncoated, round, biconvex, orange, sublingual tablets, debossed with '969' on one side and plain on other side”
969 pill
Pill with imprint 969 is orange, round, 6 mm and has been identified as Buprenorphine and Naloxone 2 mg / 0.5 mg. It is used for opioid use disorder. It is supplied by Sun Pharmaceutical Industries, Inc.
Controlled substance: Schedule III
Buprenorphine and Naloxone 2 mg / 0.5 mg
- Imprint
- 969
- Strength
- Buprenorphine 2 mg / Naloxone 0.5 mg
- Used for
- Opioid use disorder
- Color
- Orange
- Shape
- Round
- Size
- 6 mm
- Score
- No score line
- Form
- Tablet
- Manufacturer
- Sun Pharmaceutical Industries, Inc
- Drug class
- Partial opioid (pain or opioid use disorder medicine)
- NDC
- 62756-969, 62756-969-83, 62756-969-64
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
What is Buprenorphine and Naloxone used for?
Buprenorphine and Naloxone is used for opioid use disorder.
- Medicine type
- Partial opioid (pain or opioid use disorder medicine); opioid blocker
Official uses from the US prescribing label
Buprenorphine and naloxone sublingual tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and naloxone sublingual tablets should be used as part of a complete treatment plan that includes counseling and psychosocial support.
From the FDA-approved label on DailyMed (published Aug 13, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows 969 and the other side is plain.
- It is orange, round, 6 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Buprenorphine Hydrochloride, Naloxone Hydrochloride Dihydrate
Inactive: Lactose Monohydrate, Mannitol, Povidone, Unspecified, Anhydrous Citric Acid, Sodium Citrate, Unspecified Form, Fd&c Yellow No. 6, Butylated Hydroxyanisole, Magnesium Stearate, Acesulfame Potassium, Starch, Corn
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
L15
Levothyroxine 0.025 mg
Orange, round, 6 mm
Used for goiter and myxedema
-
A25
Eltrombopag 25 mg
Orange, round, 7 mm
Used for aplastic anemia and idiopathic thrombocytopenic purpura
-
E 52
Quetiapine Fumarate 25 mg
Orange, round, 6 mm
Used for bipolar disorder and schizophrenia
-
M
Levomefolate Calcium 0.451 mg
Orange, round, 6 mm
Used for anemia from low B12 or folate and low folate
-
APO MID 5
Midodrine Hydrochloride 5 mg
Orange, round, 7 mm
Used for low blood pressure on standing and bladder leaks
-
JSP 513
Levothyroxine Sodium 25 mcg
Orange, round, 7 mm
Used for goiter and myxedema
Other Buprenorphine and Naloxone pills
-
RP n2
Buprenorphine and Naloxone 2 mg / 0.5 mg
Orange, round, 6 mm
Used for opioid use disorder
Schedule III
-
A 14
Buprenorphine and Naloxone 2 mg / 0.5 mg
Orange, round, 6 mm
Used for opioid use disorder
Schedule III
-
RP n8
Buprenorphine and Naloxone 8 mg / 2 mg
Orange, round, 11 mm
Used for opioid use disorder
Schedule III
-
AN 415
Buprenorphine and Naloxone 8 mg / 2 mg
Orange, round, 11 mm
Used for opioid use disorder
Schedule III
- 7 Buprenorphine Hydrochloride and Naloxone Hydrochloride 0.7 mg / 0.18 mg White, oval, 7 mm Used for opioid use disorder Schedule III
- 1 4 Buprenorphine Hydrochloride and Naloxone Hydrochloride 1.4 mg / 0.36 mg White, triangle, 7 mm Used for opioid use disorder Schedule III
- 11 4 Buprenorphine Hydrochloride and Naloxone Hydrochloride 11.4 mg / 2.9 mg White, oval, 7 mm Used for opioid use disorder Schedule III
- 11 4 Buprenorphine Hydrochloride and Naloxone Hydrochloride 11.4 mg / 2.9 mg White, capsule, 7 mm Used for opioid use disorder Schedule III